Dr Sandra Misale works as Senior Research Associate at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY, USA. She graduated in Bio-molecular Biotechnologies in 2009 and completed her PhD training in Molecular Medicine at the University of Turin, Italy in 2014. Sandra began her post-doctoral training in 2015 at Massachusetts General Hospital, Harvard Medical School in Boston, MA and later at MSKCC in New York.

During her PhD, Dr Misale identified and characterised the molecular bases of secondary resistance to anti-EGFR targeted therapies in colorectal cancer and received the ‘Marisa Colbacchini’ award for Italian best doctorate thesis in oncological sciences. During her postdoctoral research she studied the response to KRAS G12C covalent inhibitors and antibody-drug conjugates in lung and colorectal cancers. Her current research focuses on developing rational combinations to overcome resistance to targeted therapies in melanoma, lung and colorectal cancers.

Dr Misale is the author of several papers published in peer-reviewed international journals and has been an invited speaker at national and international meetings. She is also a peer reviewer for various oncology journals.